Facial application is generally avoided because the skin is thinner and more prone to irritation. Some dermatologists may prescribe a very low-dose regimen for specific facial eczema, but this should only be done under specialist supervision.
After opening, the ointment should be used within three months. Discard any tube that shows a change in colour, texture, or odour, as potency may be compromised.
No. Tacrolimus can increase photosensitivity, so you should apply sunscreen (SPF 30 or higher) and wear protective clothing when outdoors.
It can be used sequentially with emollients and moisturisers. Combining it with other potent immunosuppressants (e.g., topical corticosteroids) is usually unnecessary and should be coordinated by a prescriber.
Yes, wash your hands thoroughly after each application to avoid accidental transfer to the eyes or other uninvolved skin areas.
Protopic is a prescription medication but not a controlled substance. Carry it in its original packaging with a copy of the prescription, and declare it if required by airline security.
Because tacrolimus suppresses local immune activity, secondary skin infections can occur more readily. Promptly report signs of infection (increased redness, swelling, pus) to your clinician.
Both reduce inflammation, but Protopic does not cause skin thinning, which is a common side effect of prolonged steroid use. Choice of therapy depends on disease severity, skin location, and patient response.
Use during pregnancy is only recommended when the expected benefit outweighs potential risk to the fetus. Discuss the decision thoroughly with an obstetrician and dermatologist.
A mild burning sensation is common initially and often resolves within a few days. If the discomfort is severe or persists, contact your healthcare provider for possible dose adjustment or alternative therapy.
Protopic is a prescription-only (POM) topical medication marketed in the United Kingdom by Astellas Pharma. Its active ingredient is tacrolimus, a calcineurin inhibitor used to manage inflammatory skin conditions. Protopic is supplied as a tube-filled ointment in two strengths: 0.03 % and 0.1 % tacrolimus. The product is approved by the Medicines and Healthcare products Regulatory Agency (MHRA) for the short-term and intermittent treatment of moderate to severe atopic dermatitis (eczema) when topical corticosteroids are inappropriate or ineffective.
Tacrolimus belongs to the class of immunomodulatory agents known as calcineurin inhibitors. By binding to the intracellular protein FKBP-12, tacrolimus forms a complex that blocks the enzyme calcineurin. This inhibition prevents the dephosphorylation and activation of the nuclear factor of activated T-cells (NF-AT), a key transcription factor for interleukin-2 (IL-2) and other cytokines that drive T-cell proliferation.
| Indication (MHRA-approved) | Typical Patient Population |
|---|---|
| Moderate to severe atopic dermatitis (eczema) | Children ≥ 2 years (0.03 % strength) and adults (0.1 % strength) who have not responded adequately to topical corticosteroids or for whom steroids are contraindicated. |
Key points
Protopic’s tacrolimus component has been investigated for several dermatological conditions outside its approved label:
Disclaimer: Off-label applications are not authorised by the MHRA. They should only be undertaken under the guidance of a qualified dermatologist, with a clear risk-benefit assessment.
These effects are usually mild and diminish with continued use or reduced frequency.
Safety tip: Patients should inform their healthcare provider of all concomitant medicines, including over-the-counter products and herbal supplements, before initiating Protopic.
This article provides educational information about Protopic and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
